Welcome to our dedicated page for China Jo-Jo Drugstores news (Ticker: $CJJD), a resource for investors and traders seeking the latest updates and insights on China Jo-Jo Drugstores stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect China Jo-Jo Drugstores's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of China Jo-Jo Drugstores's position in the market.
China Jo-Jo Drugstores (Nasdaq: CJJD), a major retailer, wholesaler, and healthcare provider in China, announced a change in its board of directors on May 31, 2024. Effective immediately, Ms. Pingfan Wu resigned from her position on the board due to personal reasons. The company clarified that her resignation was not due to any disagreements related to business operations, financial reporting, or company policies.
China Jo-Jo Drugstores, Inc. announced a registered direct offering of 1.61 million ordinary shares at a purchase price of $1.70 per share, totaling $2.74 million in gross proceeds. The offering is expected to close on May 17, 2024. The company plans to use the net proceeds for general corporate purposes and working capital. The shares are offered under an effective shelf registration statement on Form F-3.
China Jo-Jo Drugstores, Inc. announced a registered direct offering of 0.9 million ordinary shares at $1.70 per share, totaling $1.53 million. The offering is expected to close on or about April 30, 2024, with proceeds intended for general corporate purposes and working capital. The shares are offered under a shelf registration statement on Form F-3, declared effective by the SEC in December 2022.
